| From Thursday's close, the D. Boral Capital and Maxim Group targets project a potential upside of over 1,000% and 700%, respectively.
On top of those, Zacks Research provided MDCX with an "Upgrade" two months ago.
From current chart levels, do these targets and upgrade signal (Nasdaq: MDCX) to be undervalued?
#3. Medicus Pharma Strengthens Hope Through Partnership For Gorlin Syndrome Patients.
Medicus Pharma Ltd. announced a collaboration with the Gorlin Syndrome Alliance to advance compassionate use of SKINJECT™, its investigational microneedle-based doxorubicin therapy, for patients with Gorlin Syndrome.
Together, they will pursue FDA’s Expanded Access IND Program, enabling treatment for severe basal cell carcinomas while gathering real-world safety and efficacy data.
The partnership underscores Medicus’s patient-centered approach, integrating community input and innovation to address a rare, lifelong disease.
#4. Groundbreaking Expansion Of Medicus Pharma’s Global Non-Invasive Cancer Treatment Trials.
Medicus Pharma Ltd. has successfully treated the first patient in the UAE Phase 2 SKNJCT-004 trial, advancing its innovative non-invasive therapy for basal cell carcinoma (BCC).
The 36-patient study, led by Cleveland Clinic Abu Dhabi and supported by five premier hospitals, underscores Medicus’s expanding international clinical footprint.
Partnering with UAE-based IROS, the company enhances global research capabilities.
This milestone follows positive U.S. trial results and an FDA-endorsed pathway for Skinject, reinforcing Medicus’s leadership in pioneering skin cancer treatments and global biotech innovation.
#5. FDA Endorsement Boosts Medicus Pharma’s Innovative Non-Invasive Skin Cancer Therapy.
Medicus Pharma Ltd. received encouraging FDA Type C meeting feedback supporting its Skinject D-MNA treatment for non-invasive basal cell carcinoma (BCC) therapy under the 505(b)(2) pathway.
This regulatory alignment accelerates timelines, reduces development costs, and affirms Skinject’s ~$2Bn market potential.
The FDA provided constructive guidance on study design, endpoints, and formulation optimization.
With Phase 2 recruitment set to conclude in Q4 2025 and an EOP2 meeting planned in Q1 2026, Medicus strengthens its path toward anticipated commercialization by 2027. -----
We're officially reinitiating coverage on Medicus Pharma Ltd. (Nasdaq: MDCX).
Stay on the lookout for updates coming shortly. All the best, Dane James Editor Market Pulse Today
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 11/06/2025 and ending on 11/07/2025 to publicly disseminate information about (MDCX:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid six thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid forty four thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (MDCX:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/mdcx-mkvto/#details | 
